Literature DB >> 1349724

Immunobiology of experimental leishmaniasis.

I Müller1, U Fruth, J A Louis.   

Abstract

Self-cure versus uncontrolled disease progression in experimental murine cutaneous leishmaniasis depends upon a delicate interplay among various activated cells of the host's immune system. Susceptibility or resistance to infection with Leishmania major is correlated with the ability of different inbred strains of mice to produce the characteristic spectra of lymphokines upon infection. Appropriate experimental interventions now allow the modulation of these responses, providing the possibility to render genetically susceptible mice resistant to infection and, vice versa, to cause genotypically "healer" strains to express a "non-healer" phenotype. These experimental manipulations have proven to be powerful tools in the dissection of the underlying immune mechanisms and cellular parameters responsible for susceptibility and resistance, and will perhaps allow the identification of molecules of parasite origin that induce deleterious immune responses to infection with Leishmania, and thus to exclude them from future vaccines. More importantly, rational immune intervention could permit the diversion of established host-damaging immune responses to host-protective immunization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349724     DOI: 10.1007/bf00193391

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  76 in total

1.  Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide.

Authors:  F Y Liew; Y Li; S Millott
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

2.  The local cellular immune response in experimental leishmaniasis.

Authors:  M J McElrath; H W Murray; Z A Cohn
Journal:  Ann Inst Pasteur Immunol       Date:  1987 Sep-Oct

3.  Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis.

Authors:  R G Titus; G Milon; G Marchal; P Vassalli; J C Cerottini; J A Louis
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

4.  Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives.

Authors:  J Mauël; A Ransijn; Y Buchmüller-Rouiller
Journal:  J Leukoc Biol       Date:  1991-01       Impact factor: 4.962

5.  Susceptibility of inbred mice to Leishmania tropica infection: correlation of susceptibility with in vitro defective macrophage microbicidal activities.

Authors:  C A Nacy; A H Fortier; M G Pappas; R R Henry
Journal:  Cell Immunol       Date:  1983-04-15       Impact factor: 4.868

6.  Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis.

Authors:  F Y Liew; C Parkinson; S Millott; A Severn; M Carrier
Journal:  Immunology       Date:  1990-04       Impact factor: 7.397

7.  Cytokine interactions in experimental cutaneous leishmaniasis. II. Endogenous tumor necrosis factor-alpha production by macrophages is induced by the synergistic action of interferon (IFN)-gamma and interleukin (IL) 4 and accounts for the antiparasitic effect mediated by IFN-gamma and IL 4.

Authors:  S Stenger; W Solbach; M Röllinghoff; C Bogdan
Journal:  Eur J Immunol       Date:  1991-07       Impact factor: 5.532

8.  Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products.

Authors:  N E Reiner; W Ng; W R McMaster
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

9.  Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines.

Authors:  B J Holaday; M D Sadick; Z E Wang; S L Reiner; F P Heinzel; T G Parslow; R M Locksley
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

10.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.

Authors:  M D Sadick; F P Heinzel; B J Holaday; R T Pu; R S Dawkins; R M Locksley
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  6 in total

1.  Assessment of interferon-γ levels and leishmanin skin test results in persons recovered for leishmaniasis.

Authors:  Mohammad H Alimohammadian; Stephen L Jones; Haideh Darabi; Farhad Riazirad; Soheila Ajdary; Aliakbar Shabani; Mohammad A Rezaee; Mehdi Mohebali; Zohreh Hosseini; Farrokh Modabber
Journal:  Am J Trop Med Hyg       Date:  2012-07       Impact factor: 2.345

2.  Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon.

Authors:  I B Autenrieth; M Beer; E Bohn; S H Kaufmann; J Heesemann
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

3.  Naloxone Diminishes the Virulence and Modifies the Cellular Immune Responses of BALB/c Mice Infected with Leishmania major.

Authors:  Mohammad Hossein Alimohammadian; Farhad Riazi-Rad; Mahsa Asadi-Tat; Sima Darabi; Haiedeh Darabi; Vahid Khaze; Fariborz Bahrami; Soheila Ajdary
Journal:  Acta Parasitol       Date:  2020-11-19       Impact factor: 1.440

4.  Experimental progressive emphysema in BALB/cJ mice as a model for chronic alveolar destruction in humans.

Authors:  Nathachit Limjunyawong; John M Craig; H A Daniel Lagassé; Alan L Scott; Wayne Mitzner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-07-31       Impact factor: 5.464

5.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

6.  IL-23 and IL-27 Levels in Macrophages Collected from Peripheral Blood of Patients with Healing Vs Non-Healing Form of Cutaneous Leishmaniasis.

Authors:  S Tolouei; K Ghaedi; A Khamesipour; M Akbari; M Baghaei; Sj Hasheminia; M Narimani; Sh Hejazi
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.